Clinical Orthopaedics and Related Research ®

A Publication of The Association of Bone and Joint Surgeons ®

Tumor 247 articles


Femur Mass in a 43-Year-Old Woman

Yan Epelboym MPH, Kapil R. Desai MD, Roberto Garcia MD, James C. Wittig MD

Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma

Masanori Kawano MD, PhD, Ichiro Itonaga MD, PhD, Tatsuya Iwasaki MD, Hiroyuki Tsuchiya MD, PhD, Hiroshi Tsumura MD, PhD

We previously reported the combination of tumor cryotreatment with dendritic cells to promote antitumor immunity. The effect of the combination treatment with dendritic cells and antitransforming growth factor-β (anti-TGF-β) antibody on the elimination of regulatory T cells and the inhibition of tumor growth was investigated.

Simultaneous Anterior and Posterior Synovectomies for Treating Diffuse Pigmented Villonodular Synovitis

Wei-Ming Chen MD, Po-Kuei Wu MD, Chien-Lin Liu MD

The current treatment methods for diffuse intraarticular or extraarticular type pigmented villonodular synovitis (PVNS) include arthroscopic synovectomy or staged anterior and posterior open synovectomies. However, it is unclear whether simultaneous anterior and posterior synovectomies achieve local control and recovery of function.

Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group

Michael S. Isakoff MD, Donald A. Barkauskas PhD, David Ebb MD, Carol Morris MD, G. Douglas Letson MD

The pelvis is an infrequent site of osteosarcoma and treatment requires surgery plus systemic chemotherapy. Poor survival has been reported, but has not been confirmed previously by the Children’s Oncology Group (COG). In addition, survival of patients with pelvic osteosarcomas has not been compared directly with that of patients with nonpelvic disease treated on the same clinical trials.

Orthopaedic Case of the Month: Ossified Calf Mass in a 32-year-old Woman

Eniola T. Obadina MD, Donna G. Blankenbaker MD, Kirkland W. Davis MD, John P. Heiner MD

Does Limb-salvage Surgery Offer Patients Better Quality of Life and Functional Capacity than Amputation?

Farbod Malek MD, Jeremy S. Somerson MD, Shannon Mitchel MD, Ronald P. Williams MD

Patients with aggressive lower extremity musculoskeletal tumors may be candidates for either above-knee amputation or limb-salvage surgery. However, the subjective and objective benefits of limb-salvage surgery compared with amputation are not fully clear.

Function After Injection of Benign Bone Lesions with a Bioceramic

Yale A. Fillingham BA, Brett A. Lenart MD, Steven Gitelis MD

A novel calcium sulfate–calcium phosphate composite injectable bone graft substitute has been approved by the FDA for filling bone defects in a nonweightbearing application based on preclinical studies. Its utility has not been documented in the literature.

Similar Survival but Better Function for Patients after Limb Salvage versus Amputation for Distal Tibia Osteosarcoma

Andreas F. Mavrogenis MD, Caterina Novella Abati MD, Carlo Romagnoli MD, Pietro Ruggieri MD, PhD

Amputation has been the standard surgical treatment for distal tibia osteosarcoma. Advances in surgery and chemotherapy have made limb salvage possible. However, it is unclear whether limb salvage offers any improvement in function without compromising survival.

Case Report: Bone Tumor of the Scapula in a Patient Undergoing Liver Transplantation

Zhen-Qi Ding MD, Hai-Fang Zhang MD, Liang-Qi Kang MD, Mo Sha MD

De novo malignancies are serious complications in the late postoperative period after liver transplantation. The most common de novo tumors are skin malignancies, posttransplantation lymphoproliferative disorder, tumors of the head and neck, and Kaposi’s sarcoma. Such posttransplant de novo malignancies are apparently rarely found in bone.